These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23238770)

  • 1. Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.
    Tóth M; Varrone A; Steiger C; Laszlovszky I; Horváth A; Kiss B; Gyertyán I; Adham N; Halldin C; Gulyás B
    Synapse; 2013 May; 67(5):258-64. PubMed ID: 23238770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.
    Gyertyán I; Kiss B; Sághy K; Laszy J; Szabó G; Szabados T; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Csongor EÁ; Domány G; Tihanyi K; Szombathelyi Z
    Neurochem Int; 2011 Nov; 59(6):925-35. PubMed ID: 21767587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.
    Seneca N; Finnema SJ; Laszlovszky I; Kiss B; Horváth A; Pásztor G; Kapás M; Gyertyán I; Farkas S; Innis RB; Halldin C; Gulyás B
    Psychopharmacology (Berl); 2011 Dec; 218(3):579-87. PubMed ID: 21625907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA.
    Finnema SJ; Halldin C; Bang-Andersen B; Gulyás B; Bundgaard C; Wikström HV; Farde L
    Synapse; 2009 May; 63(5):378-89. PubMed ID: 19173265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride.
    Seneca N; Finnema SJ; Farde L; Gulyás B; Wikström HV; Halldin C; Innis RB
    Synapse; 2006 Apr; 59(5):260-9. PubMed ID: 16416444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.
    Wilson AA; McCormick P; Kapur S; Willeit M; Garcia A; Hussey D; Houle S; Seeman P; Ginovart N
    J Med Chem; 2005 Jun; 48(12):4153-60. PubMed ID: 15943487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F-MCL-524, an (18)F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study.
    Finnema SJ; Stepanov V; Nakao R; Sromek AW; Zhang T; Neumeyer JL; George SR; Seeman P; Stabin MG; Jonsson C; Farde L; Halldin C
    J Nucl Med; 2014 Jul; 55(7):1164-70. PubMed ID: 24790219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system.
    Galineau L; Wilson AA; Garcia A; Houle S; Kapur S; Ginovart N
    Synapse; 2006 Aug; 60(2):172-83. PubMed ID: 16715499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.
    McCormick PN; Kapur S; Reckless G; Wilson AA
    Synapse; 2009 Nov; 63(11):998-1009. PubMed ID: 19598174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
    Veselinović T; Paulzen M; Gründer G
    Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.
    Searle G; Beaver JD; Comley RA; Bani M; Tziortzi A; Slifstein M; Mugnaini M; Griffante C; Wilson AA; Merlo-Pich E; Houle S; Gunn R; Rabiner EA; Laruelle M
    Biol Psychiatry; 2010 Aug; 68(4):392-9. PubMed ID: 20599188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
    J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist.
    Xu J; Vangveravong S; Li S; Fan J; Jones LA; Cui J; Wang R; Tu Z; Chu W; Perlmutter JS; Mach RH
    Neuroimage; 2013 May; 71():168-74. PubMed ID: 23333701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo comparison of [³H](+)-PHNO and [³H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D₃ from D₂ receptor sites.
    Kiss B; Horti F; Bobok A
    Synapse; 2011 Jun; 65(6):467-78. PubMed ID: 20936685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
    Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.